Aleksei Kovalev

Cloning, heterologous expression and partial purification of IF2

Cloning, heterologous expression and purification of the IF2 translation initiation factor (Mycobacterium tuberculosis)

• Broschiertes Buch

Produktbeschreibung

It is important to evaluate the role of the IF2 within the bacterial translation regulatory mechanism as well as to pose the IF2 as a molecular target for repurposed non-steroidal anti-inflammatory drugs (NSAIDS). The aim of this project is to identify a novel and an effective therapeutic endogenous molecular target in Mycobacterium tuberculosis. In this study, I have identified, cloned, expressed and partially purified the novel putative endogenous therapeutic target for various non-steroidal anti-inflammatory drugs (NSAIDs) from H37Rv strain of Mycobacterium tuberculosis: putative mycobacterial infB, Rv2839c encoded protein which is putative protein translation initiation factor 2 (IF2) in a few species of mycobacteria. I conclude it may lead us to the discovery of the new anti-tubercular role of some old inexpensive NSAIDs and/or their derivatives as effective drugs against IF2 of Mycobacterium tuberculosis.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Seitenzahl: 84
• Erscheinungstermin: 25. November 2016
• Englisch
• Abmessung: 220mm x 150mm x 6mm
• Gewicht: 128g
• ISBN-13: 9783330009349
• ISBN-10: 3330009349
• Artikelnr.: 47165845

Autorenporträt

In 2013, I graduated from the Birkbeck College, University of London in the UK with a two years degree in Clinical Microbiology. The most important for me was my participation in cloning, heterologous expression and purification of a couple of putative molecular drug targets from Mycobacterium tuberculosis, with which I got Merit mark.